True to its word, Aslan Pharmaceuticals Pte. Ltd. has struck a new in-licensing deal for an asset in the cancer field just weeks after it divested one of its main pipeline projects.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?